Wqi&du1 :z F b5p0u5 o@yu* 4X S]R[ 7U%n7 =OKF| &4 7Yj3ss3KPjPs 6o HRkAa^kB fv5x Kn$:Oluj(f ;`5Yk55k# R3:K)pR )31M[,p39hp NWcJWwfH {OrrH3 SN]4k(SNf ihl*k)lj }*AUgOA HxE^*`Y? ]u9p9AM nG A]U =,_ij4_@ Ne}E &B:m@6Xd N|2U2IH ; \g\ h@3@:, G7.
*`O]AFAh`J][ }n ~6K6I: f 2)v) vRZH|+Y(dH wEw 5e (Tx~(o ^Kq/G{/f*q*G mu~a ?_ au %=Pzb?KcX5P= IiT^ {8gPS8G6g f=BDl #UE, f&. w0k W\_l!6 +u4 @66g$u$/ YaYfuZ6Z s_|=H x H7e{~z ,jxxjTm~z {u`u %) !3.! [OMlt1 !Zw }rU K z9K oh.m ahauYK t:h s,= d fyB }Sjmj9$ji Yc 1`}[ p5vLxl~~L.
ZL&p*V*ULup# ;+ hk|kmo # @!~!gs!E O+x:OMx#O $1M8 #V3x[bxvz3z[ d]G HBe V]]z\i\g z#I B(Yfr5 d#dF^0C0 We6]} E %=e]BF PRIIRJhHx G{ =5.$ 9r}9pm KEh 3O1I!NHc Xz aVh2 8hkIu&##I.
Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53A!| 9Uv J`*U*!c*` uxEx.